Your Best Stock
Stocks Biotechnology REGN

Regeneron Pharmaceuticals REGN

US equityMarket cap rank #199BiotechnologyInfectious Disease
$791.33
−$10.50 (-1.31%)
Market open · Sep 24, 1:10 pm ET
After hours $801.82 0.00%
Open$801.59
Prev close$801.82
Day range$789.41 – $807.21
Volume246.9K
Market cap$81.47B
P/E (TTM)19.6
Dividend yield0.46%

Earnings

Average move on report day±4.7%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+11.8%
Worst reaction-9.2%

Stock move on the day after each report

+3.5%2023/Q3-1.3%2023/Q4+3.8%2024/Q1+1.3%2024/Q2-9.2%2024/Q3+4.5%2024/Q4-6.9%2025/Q1+2.5%2025/Q2+11.8%2025/Q3-1.1%2025/Q4-6.2%2026/Q1+6.2%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q230 Jul 2026Pre Market±40.0%+6.17%Within range
2026/Q129 Apr 2026Pre Market±49.7%-6.21%Within range
2025/Q430 Jan 2026Pre Market±46.3%-1.07%Within range
2025/Q328 Oct 2025Pre Market±30.9%+11.82%Within range
2025/Q21 Aug 2025Pre Market±46.9%+2.46%Within range
2025/Q129 Apr 2025Pre Market±35.8%-6.87%Within range
2024/Q44 Feb 2025Pre Market±37.2%+4.53%Within range
2024/Q331 Oct 2024Pre Market±36.2%-9.17%Within range
2024/Q21 Aug 2024Pre Market±53.9%+1.29%Within range
2024/Q12 May 2024Pre Market±37.8%+3.78%Within range
2023/Q42 Feb 2024Pre Market±36.8%-1.32%Within range
2023/Q32 Nov 2023Pre Market±39.7%+3.48%Within range
2023/Q23 Aug 2023Pre Market±31.6%+5.37%Within range
2023/Q14 May 2023Pre Market±32.6%-6.14%Within range
2022/Q33 Nov 2022Pre Market±31.4%-0.24%Within range
2022/Q23 Aug 2022Pre Market±36.5%+5.88%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Collaboration revenue$2.46B 57.2%
  • EYLEA HD$596.30M 13.9%
  • EYLEA$412.20M 9.6%
  • Libtayo$342.60M 8.0%
  • Other revenue$193.30M 4.5%
  • Libtayo$146.80M 3.4%
  • Praluent$74.70M 1.7%
  • Evkeeza$53.30M 1.2%
  • Lynozyfic$16.50M 0.4%

Latest reported quarter: Q2, ended Jun 2026

Revenue$4.29B+16.7% YoY
Operating profit$1.42B+30.4% YoY
Net profit$1.30B-6.8% YoY
Diluted EPS$12.23-4.5% YoY
Free cash flow$521.80M-29.3% YoY
Operating cash flow$813.00M

Revenue, last 8 quarters

$3.7BSep '24$3.8BDec '24$3.0BMar '25$3.7BJun '25$3.8BSep '25$3.9BDec '25$3.6BMar '26$4.3BJun '26

Net profit, last 8 quarters

$1.3BSep '24$917.7MDec '24$808.7MMar '25$1.4BJun '25$1.5BSep '25$844.6MDec '25$727.2MMar '26$1.3BJun '26

Profitability & balance sheet

Gross margin84.9%
Operating margin26.9%
Net margin27.9%
Return on equity14.0%
Return on assets10.8%
Return on invested capital11.1%
Current ratio3.34
Liabilities / assets24.0%
Cash & investments$7.99B
Total debt$1.99B
Net cash (debt)$6.01B
Free cash flow / sales23.0%
Scroll to Top